Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR Jr, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW; Passive Immunity Trial for Our Nation (PassITON) Investigators. Self WH, et al. Among authors: collins jb. Trials. 2021 Mar 20;22(1):221. doi: 10.1186/s13063-021-05171-2. Trials. 2021. PMID: 33743799 Free PMC article.
Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
Self WH, Stewart TG, Wheeler AP, El Atrouni W, Bistran-Hall AJ, Casey JD, Cataldo VD, Chappell JD, Cohn CS, Collins JB, Denison MR, de Wit M, Dixon SL, Duggal A, Edwards TL, Fontaine MJ, Ginde AA, Harkins MS, Harrington T, Harris ES, Hoda D, Ipe TS, Jaiswal SJ, Johnson NJ, Jones AE, Laguio-Vila M, Lindsell CJ, Mallada J, Mammen MJ, Metcalf RA, Middleton EA, Mucha S, O'Neal HR, Pannu SR, Pulley JM, Qiao X, Raval JS, Rhoads JP, Schrager H, Shanholtz C, Shapiro NI, Schrantz SJ, Thomsen I, Vermillion KK, Bernard GR, Rice TW. Self WH, et al. Among authors: collins jb. Res Sq [Preprint]. 2021 Mar 2:rs.3.rs-227796. doi: 10.21203/rs.3.rs-227796/v1. Res Sq. 2021. PMID: 33688640 Free PMC article. Updated. Preprint.
Chemotherapy safe handling practices in Ethiopia: A comprehensive multi-center evaluation.
Webb N, Matys S, Collins JB, Garcia J, Worku K, Lines M, Hirata H, Dark E, Brooks C, Buhlinger K, Fentie AM, Roberts MC, Muluneh B. Webb N, et al. Among authors: collins jb. J Oncol Pharm Pract. 2024 May 2:10781552241249420. doi: 10.1177/10781552241249420. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38695136 Free article.
Quantitative tests of albendazole resistance in beta-tubulin mutants.
Collins JB, Stone SA, Koury EJ, Paredes AG, Shao F, Lovato C, Chen M, Shi R, Li AY, Candal I, Al Moutaa K, Moya N, Andersen EC. Collins JB, et al. bioRxiv [Preprint]. 2024 Apr 13:2024.04.11.589070. doi: 10.1101/2024.04.11.589070. bioRxiv. 2024. PMID: 38665774 Free PMC article. Preprint.
Barriers and facilitators associated with implementing interventions to support oral anticancer agent adherence in academic and community cancer center settings.
Muluneh B, Muir MA, Collins JB, Proco D, Mackler E, Leak Bryant A, Wood WA, Tilkens M, Reichard JS, Foster M, Gatwood J, Wheeler SB, Zullig LL, Elston Lafata J. Muluneh B, et al. Among authors: collins jb. PLoS One. 2023 Jul 21;18(7):e0286630. doi: 10.1371/journal.pone.0286630. eCollection 2023. PLoS One. 2023. PMID: 37478078 Free PMC article.
113 results